Sökning: onr:"swepub:oai:DiVA.org:su-113955" > Advances in the the...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03739naa a2200577 4500 | |
001 | oai:DiVA.org:su-113955 | |
003 | SwePub | |
008 | 150216s2015 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:130468482 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-1139552 URI |
024 | 7 | a https://doi.org/10.1586/14737175.2015.9956372 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1304684822 URI |
040 | a (SwePub)sud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Hampel, Harald4 aut |
245 | 1 0 | a Advances in the therapy of Alzheimer's disease :b targeting amyloid beta and tau and perspectives for the future |
264 | c 2014-12-24 | |
264 | 1 | b Informa UK Limited,c 2015 |
338 | a print2 rdacarrier | |
500 | a AuthorCount:10; | |
520 | a Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis- and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre- and asymptomatic at-risk stages of AD. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Geriatrik0 (SwePub)302222 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Geriatrics0 (SwePub)302222 hsv//eng |
653 | a Alzheimer's disease | |
653 | a amyloid beta immunotherapy | |
653 | a bapineuzumab | |
653 | a biological markers | |
653 | a clinical trials | |
653 | a prevention | |
653 | a randomized controlled trials center dot systems biology | |
653 | a solanezumab | |
653 | a tau immunotherapy | |
700 | 1 | a Schneider, Lon S.u Karolinska Institutet4 aut |
700 | 1 | a Giacobini, Ezio4 aut |
700 | 1 | a Kivipelto, Miiau Stockholms universitet,Centrum för forskning om äldre och åldrande (ARC), (tills m KI),Karolinska Institutet, Sweden; University of Eastern Finland, Finland4 aut |
700 | 1 | a Sindi, Shireenu Stockholms universitet,Centrum för forskning om äldre och åldrande (ARC), (tills m KI),Karolinska Institutet, Sweden4 aut |
700 | 1 | a Dubois, Bruno4 aut |
700 | 1 | a Broich, Karl4 aut |
700 | 1 | a Nistico, Robert4 aut |
700 | 1 | a Aisen, Paul S.4 aut |
700 | 1 | a Lista, Simone4 aut |
710 | 2 | a Karolinska Institutetb Centrum för forskning om äldre och åldrande (ARC), (tills m KI)4 org |
773 | 0 | t Expert Review of Neurotherapeuticsd : Informa UK Limitedg 15:1, s. 83-105q 15:1<83-105x 1473-7175x 1744-8360 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-113955 |
856 | 4 8 | u https://doi.org/10.1586/14737175.2015.995637 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:130468482 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy